Juvenile Recurrent Respiratory Papillomatosis: Establishment of a French National Cohort (PRR : National Cohort " REPA ")
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorImagine Institute
About this trial
Recurrent respiratory papillomatosis (RRP) is a rare disease. However, it is the most common benign laryngeal tumor in children. To date, no epidemiological data are available in France. The aim of this study is to establish the epidemiology of juvenile PPR.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with juvenile PRR (disease onset before age 18)
The MALO CRMR
One of the MALO network's CCMRs
One of the main correspondent centers
Disqualifiers
Patients objecting to the collection of their personal data
Parents of minor patients objecting to the collection of their child's personal data
Trial population
All patients with juvenile PRR in France
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Epidemiology of juvenile RRP in France by clinical information
age at onset of disease, symptoms, severity score, intensity of disease characterized by need for endoscopies
Time frame
10 years2
Epidemiology of juvenile PRR in France according to vaccine and adjuvant therapeutic information
Vaccination and adjuvant therapy information
Time frame
10 years3
Epidemiology of juvenile PRR in France by paraclinical information
results of pulmonary imaging, genetic, anatomopathological and immunological tests
Time frame
10 yearsSecondary outcomes
1
Define standardized management of juvenile RRP
Correlations between disease progression and frequency of follow-up, as well as treatments implemented (therapeutic or surgical interventions)
Time frame
10 years2
Therapeutic management of RRP
* Frequency of therapeutic surgery * Use of adjuvant therapies
Time frame
10 years3
Prevention of RRP
Analysis of national vaccination coverage with a vaccine immunizing against HPV 6 and 11
Time frame
10 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov